Johns Hopkins Sjögren’s Center

Home / Research / A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe primary Sjögren’s Syndrome

A randomized, double-blind, placebo-controlled multicenter phase 2 dose-ranging study to assess the safety and efficacy of multiple VAY736 doses administered subcutaneously in patients with moderate to severe primary Sjögren’s Syndrome

Each day research and clinical trials are being conducted to unveil new medications, therapies and diagnostic tools for Sjögren’s syndrome and its symptoms.  The link below contains information about a Sjögren’s clinical research study (JHM IRB00138310) being held in the Baltimore, MD area.

This study includes individuals between 18-65 years of age and tests a trial drug for patients with active Sjögren’s syndrome. The study is taking place under the direction of Dr. Thomas Grader-Beck (Principal Investigator), rheumatologist and Sjögren’s syndrome specialist.

For more information about this study, please click HERE

For more information about trials currently recruiting at our center, please contact Susan Robinson, Research Program Coordinator:

  • Email: srobin95@jhmi.edu
  • Phone: 410-550-6492

Use of this Site

All information contained within the Johns Hopkins Jerome L. Green Sjogren’s Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.